Monatepil maleate (AJ-2615) is a potent and orally active Ca2+-channel antagonist and a noncompetitive ACAT inhibitor. Monatepil maleate decreases blood pressure and improves plasma lipid metabolism. Monatepil maleate has the potential for the research of hyperlipidemia[1][2].
Definition
ChEBI: Monatepil maleate is a dibenzothiepine.
in vivo
Monatepil maleate (30 mg/kg; p.o.; once daily for 9 weeks) improves plasma lipid metabolism[1].
Monatepil maleate (30 mg/kg; p.o.; once daily for 6 weeks) inhibits ACAT activity and esterifies cholesterol content in high cholesterol diet monkeys[2].
Animal Model:
8 weeks, Male japanese white rabbits (high cholesterol diet-fed)[1]
4-7 kg, 4-7 years monkeys (high cholesterol diet for 6 months)[2]
Dosage:
30 mg/kg
Administration:
P.o.; once daily for 6 weeks
Result:
Inhibited the increases of ACAT activity and esterified cholesterol content.
References
[1] Ikeno A, et al. Effects of monatepil maleate, a new Ca2+ channel antagonist with alpha1-adrenoceptor antagonistic activity, on cholesterol absorption and catabolism in high cholesterol diet-fed rabbits. Jpn J Pharmacol. 1998 Nov;78(3):303-12. DOI:10.1254/jjp.78.303 [2] Sumiya T, et al. Inhibitory effect of monatepil maleate on acyl-CoA:cholesterol acyltransferase activity in the liver of cholesterol-fed Japanese monkeys. Am J Hypertens. 1997 Jul;10(7 Pt 1):779-85. DOI:10.1016/s0895-7061(97)00066-6